Clinical Trial Summary:
Successful clinical studies conducted in China and Mexico have shown that Sucanon® is an effective treatment for Type-2 diabetes without the serious cardiovascular risks (heart attacks) that have been associated with other insulin sensitizers, including the leading drugs in this category - Avandia®, Actos®, and Rezulin®.
Sucanon® clinical trials (see Clinical Results for more detailed information on trial results) were shown to reduce the problems and symptoms of Type II Diabetes:
High blood sugar: Clinical studies have shown that Sucanon® reduces blood sugar readings by about 25% - 30% and brings high blood sugar back into the normal range (non-fasting blood sugar is above 200 mg/dL (milligrams per deciliter) or fasting blood sugar is above 126 mg/dL).
Fatigue: Clinical studies have shown that Sucanon® reduces fatigue. Fatigue is a frequent symptom of Type II Diabetes or a pre-diabetic condition called Impaired Glucose Tolerance.
Weight gain: Clinical studies have shown that people who have taken Sucanon® report weight loss along with increased energy. Very often, people who are diabetic or pre-diabetic gain weight because their insulin-resistance is leading to sugar being converted into fat instead of being burned to produce energy.
Excess thirst and urination: Clinical studies have shown that Sucanon® reduces excess thirst and excess urination. Higher-than-normal levels of blood sugar instigate thirst, which in turn leads to increased frequency of urination.
High cholesterol and triglyceride levels: Clinical studies have shown that Sucanon® reduces the levels of cholesterol and triglycerides. People who are diabetic or pre-diabetic often have elevated cholesterol and triglyceride levels. Elevated cholesterol and triglycerides significantly increase the risk of heart disease.
Side effects: Clinical studies have shown that Sucanon® showed no side effects. This sets Sucanon® apart from many other anti-diabetic products, which can have effects on digestion, the liver, or the heart.
Toxicity: Clinical studies have shown that Sucanon® toxicity was undistinguishable from the placebo. In addition, Sucanon® showed no carcinogenicity, mutagenicity, and teratogenicity in mice.